-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 14, Hanyu Pharmaceutical issued a reminder that atosiban acetate injection has passed the consistency evaluation of generic drugs.
So far, the company has 6 peptide products that have been evaluated
.
Prior to this, Yangzijiang Guangzhou Hairui Pharmaceutical's atosiban acetate injection was approved as a supplementary application, and it is the third company that has passed the evaluation of this product
.
According to data from Minet.
com, the sales of terminal atosiban acetate injection in Chinese public medical institutions will exceed 300 million yuan in 2020, and the first half of 2021 will increase by more than 50% year-on-year
.
On January 13, 2022, the drug approval certificate is pending information release.
According to the data, atosiban acetate injection is a competitive oxytocin antagonist for receptors in the uterus, decidua, and fetal membranes
.
Sales of terminal atosiban acetate injection in public medical institutions in China in recent years (unit: 100 million yuan) Source: terminal competition pattern of public medical institutions in China According to data from Minet.
com, in 2020, China's urban public hospitals, county-level public hospitals, and urban community centers And township health centers (referred to as Chinese public medical institutions) terminal atosiban acetate injection sales of more than 300 million yuan, a year-on-year increase of more than 50% in the first half of 2021
.
There are 6 companies with production approval for this product, Hainan Zhonghe Pharmaceutical has the largest market share, Ferring Pharmaceuticals and Yangzijiang Guangzhou Hairui Pharmaceutical ranked second and third
.
Prior to this, atosiban acetate injection has been reviewed by 3 companies.
Among them, Hainan Zhonghe Pharmaceutical Co.
, Ltd.
and Yangzijiang Guangzhou Hairui Pharmaceutical Co.
, Ltd.
were approved for supplementary applications.
Approval is regarded as a review
.
This time, Hanyu Pharmaceutical's Atosiban Acetate Injection was approved as a supplementary application for consistency evaluation, becoming the 4th company that has passed the evaluation of this product
.
Hanyu Pharmaceutical stated that the company's atosiban acetate injection was approved for marketing in China in December 2019, and was approved for marketing in Spain and Germany in 2020.
It is the company's first injection product that has been approved for marketing in EU countries
.
Up to now, the company has 6 peptide products that have passed the consistency evaluation
.
At the close of trading on January 14, Hanyu Pharmaceutical's share price rose by 20%, with a total market value of more than 15 billion yuan
.
So far, the company has 6 peptide products that have been evaluated
.
Prior to this, Yangzijiang Guangzhou Hairui Pharmaceutical's atosiban acetate injection was approved as a supplementary application, and it is the third company that has passed the evaluation of this product
.
According to data from Minet.
com, the sales of terminal atosiban acetate injection in Chinese public medical institutions will exceed 300 million yuan in 2020, and the first half of 2021 will increase by more than 50% year-on-year
.
On January 13, 2022, the drug approval certificate is pending information release.
According to the data, atosiban acetate injection is a competitive oxytocin antagonist for receptors in the uterus, decidua, and fetal membranes
.
Sales of terminal atosiban acetate injection in public medical institutions in China in recent years (unit: 100 million yuan) Source: terminal competition pattern of public medical institutions in China According to data from Minet.
com, in 2020, China's urban public hospitals, county-level public hospitals, and urban community centers And township health centers (referred to as Chinese public medical institutions) terminal atosiban acetate injection sales of more than 300 million yuan, a year-on-year increase of more than 50% in the first half of 2021
.
There are 6 companies with production approval for this product, Hainan Zhonghe Pharmaceutical has the largest market share, Ferring Pharmaceuticals and Yangzijiang Guangzhou Hairui Pharmaceutical ranked second and third
.
Prior to this, atosiban acetate injection has been reviewed by 3 companies.
Among them, Hainan Zhonghe Pharmaceutical Co.
, Ltd.
and Yangzijiang Guangzhou Hairui Pharmaceutical Co.
, Ltd.
were approved for supplementary applications.
Approval is regarded as a review
.
This time, Hanyu Pharmaceutical's Atosiban Acetate Injection was approved as a supplementary application for consistency evaluation, becoming the 4th company that has passed the evaluation of this product
.
Hanyu Pharmaceutical stated that the company's atosiban acetate injection was approved for marketing in China in December 2019, and was approved for marketing in Spain and Germany in 2020.
It is the company's first injection product that has been approved for marketing in EU countries
.
Up to now, the company has 6 peptide products that have passed the consistency evaluation
.
At the close of trading on January 14, Hanyu Pharmaceutical's share price rose by 20%, with a total market value of more than 15 billion yuan
.
